6472 Borui: Completion of Acquisition of Biologics CDMO Operations Assets in Maryland, USA

Disclosure Date: July 3, 2026 Announcement Date: July 2, 2026 Announcement Time: 21:30:11 Company Code: 6472 Company Name: Borui Subject: Announcement of Completion of Acquisition of Biologics CDMO Operations in Maryland, USA Applicable Clause: Item 51 Factual Date: July 2, 2026

1. Factual Date: July 2, 2026 2. Company Name: Borui Pharmaceutical Co., Ltd. 3. Relationship with Company (enter 'Company' or 'Subsidiary'): Company 4. Cross-shareholding Ratio: Not applicable 5. Reason for Occurrence: Today, the company fulfilled the payment of the acquisition price, and pursuant to mutual agreement, the closing date of this transaction was set as June 30, Eastern Time. Upon completion, the wholly-owned subsidiary Bora Biologics USA, LLC will acquire the divested biologics CDMO operational assets from MacroGenics (NASDAQ: MGNX), including the large-molecule manufacturing facility in Rockville, Maryland, and the warehouse center in Frederick. Simultaneously, the company will enter into a long-term CDMO service agreement with MacroGenics. This acquisition will help establish a reliable U.S.-based biologics manufacturing platform, creating a fully integrated, end-to-end CDMO platform spanning drug substance and drug product capabilities, strengthening global CDMO presence and enhancing international visibility. 6. Countermeasures: None 7. Other Matters to be Disclosed (If the subject of the event or resolution is a publicly listed company or above, this material information also qualifies as a matter under Article 7, Paragraph 9 of the Enforcement Rules of the Securities Trading Act that significantly affects shareholders' rights or securities prices): None